Primary Endpoint First data on efficacy of the treatment with azelastine nasal spray will be assessed by the decrease in median virus load of SARS-CoV-2 between the treatment groups via regular quantitative PCR measurements from nasopharyngeal swabs. Primary endpoint of the efficacy of azelastine nasal spray in COVID-positive patients is the baseline adjusted course of the median of virus load in nasopharyngeal swabs of the three treatment groups at any of the six timepoints (day 2, day 3, day 4, day 5, day 8 and day 11) after baseline (day 1). Comparisons will be made via regularly performed quantitative PCR measurements from nasopharyngeal swabs.

Primary Endpoint First data on efficacy of the treatment with azelastine nasal spray will be assessed by the decrease in median virus load of SARS-CoV-2 between the treatment groups via regular quantitative PCR measurements from nasopharyngeal swabs. Primary endpoint of the efficacy of azelastine nasal spray in COVID-positive patients is the baseline adjusted course of the median of virus load in nasopharyngeal swabs of the three treatment groups at any of the six timepoints (day 2, day 3, day 4, day 5, day 8 and day 11) after baseline (day 1). Comparisons will be made via regularly performed quantitative PCR measurements from nasopharyngeal swabs.